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Abstract
The aim of the study was to investigate trajectories of social functioning in young people
with first-episode psychosis (FEP) with and without cannabis misuse using a secondary
analysis of data from the Episode-II trial. Forty-two young people with FEP and comorbid
cannabis use disorder were compared with 39 young people with FEP but without a canna-
bis use disorder. Social functioning was assessed every 6 months during a 30-month fol-
low-up. Multilevel linear growth curve modeling was used to compare the social functioning
trajectories over time for those with and without cannabis misuse. Cannabis misuse was not
associated with social functioning at baseline assessment. Over a 30-month follow-up, FEP
patients without cannabis disorder showed significant improvements in their social function-
ing, whereas patients with cannabis misuse at baseline displayed no such improvement.
Patients with and without cannabis misuse differed significantly in their levels of social func-
tioning after 24 months. Similar results were obtained after adjusting for potential confound-
ers (i.e., age, gender, negative symptoms, premorbid functioning, DSM-IV diagnoses,
baseline social functioning and other substance use). In the context of a specialized early
intervention service, patients with cannabis misuse at baseline did not attain the improve-
ments in social outcomes observed in their counterparts without cannabis misuse. There is
a need to develop effective interventions to reduce cannabis misuse to ultimately improve
social outcomes in young people with psychosis.
Introduction
Cannabis is the most widely used illicit substance in the world: there are about 180 million can-
nabis users worldwide [1]. People with psychotic disorders have higher rates of cannabis use
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compared with the population at large [2]. As a result, cannabis use disorders are common in
schizophrenia patients, particularly in younger and first-episode patient samples [3].
While systematic reviews of cannabis use in psychosis have shown that people who have
used cannabis have an increase in incidence of psychosis of about 40% [4], the impact of canna-
bis use on the outcome of patients already suffering from psychotic disorders remains unclear.
The use of cannabis is fairly consistently associated with increased risk of relapse or rehospitali-
sation and with decreased treatment adherence. However, evidence for associations with other
treatment outcomes is rather equivocal [5].
Although social dysfunction is a core feature of psychotic disorders, little attention has been
paid until recently to the impact of cannabis use on social impairments. The few longitudinal
studies that have examined this relationship in psychotic disorders have largely supported the
notion that cannabis use has a detrimental effect on social outcomes [6–9]. However, some
studies have not found this association [10,11], and some have found that social outcome was
predicted by changes in cannabis use over time [12,13] or that negative social outcomes were
associated with persistent cannabis use rather than with baseline status [14]. These divergent
findings may be explained by methodological differences such as disparity in the samples, the
time between assessments, or in the covariates used to control for potential confounders (e.g.,
illness severity or baseline social functioning). It has been recommended that research in this
realm should have a longitudinal design, with repeated measures as well as adjustment for
baseline levels of the outcome measure and other relevant confounding variables [5].
The aim of this study was to examine the predictive value of cannabis misuse at baseline on
social functioning, and the potentially different social functioning trajectories of those with
cannabis misuse compared to those with no cannabis misuse in a sample of young remitted
FEP patients over a period of 30 months.
Method
Participants
In the present study we analysed data from all 81 participants in the Episode II trial as one co-
hort. The Episode II trial compared Treatment as Usual (TAU) with a combined family and in-
dividual Relapse Prevention Treatment (RPT) plus TAU within two specialist FEP services.
There were 6 assessment time points: baseline, 7, 12, 18, 24, and 30 months [15–18]. Patients
from the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne and from
JIGSAW, Barwon Health in Geelong, Victoria, Australia, were recruited between November
2003 andMay 2005. The study inclusion criteria were a diagnosis of a first episode of a Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth Edition—Text Revision (DSM-IV-TR)
psychotic disorder [19], less than 6 months of prior treatment with antipsychotic medications,
age 15–25 years inclusive, and remission on positive symptoms of psychosis. Remission was de-
fined as 4 weeks or more of scores of 3 (mild) or below on the subscale items hallucinations, un-
usual thought disorder, conceptual disorganization, and suspiciousness on the expanded
version of the Brief Psychiatric Rating Scale [BPRS; 20]. Exclusion criteria were ongoing active
positive psychotic symptoms, severe intellectual disability, inability to converse in or read En-
glish, and participation in previous CBT trials.
Ethics Statement
The study was approved by the Northwestern Mental Health and the Barwon Health Research
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Assessment
The Structured Clinical Interview for DSM-IV (SCID), including psychoses, substance depen-
dence and abuse, mood disorders and personality disorders was completed at baseline [21].
Symptom measures included the Montgomery–Åsberg Depression Rating Scale [MADRS; 22],
which provides a measure of the severity of depressive symptoms; the BPRS, which provides se-
verity ratings across a broad range of psychotic and non-psychotic symptoms; and the Scale for
the Assessment of Negative Symptoms [SANS; 23], a measure of negative symptoms. The Pre-
morbid Adjustment Scale (PAS) was used to evaluate pre-morbid functioning [24]. To focus
on early adjustment, we created an average score for social and academic domains based only
on the first three areas of development (i.e. childhood, early adolescence, late adolescence).
Full-Scale IQ (FSIQ) was estimated based on the performance on the Wechsler Test of Adult
Reading (WTAR) [25].
Social functioning was assessed using the Social and Occupational Functioning Assessment
Scale (SOFAS [26]). The SOFAS was developed as an additional AXIS V clinician-rated mea-
sure of global social and occupational functioning, and is not directly influenced by the overall
severity of the individual's psychological symptoms. The SOFAS yields an overall score of cur-
rent functioning ranging from 0 to 100, with lower scores representing lower functioning. This
scale has been used as a measure of functional outcome in FEP studies [27].
Cannabis misuse was defined as meeting DSM-IV-TR criteria for cannabis abuse or depen-
dence at baseline assessment which was assessed by the SCID. Problematic cannabis use at
each subsequent time point was determined using the Alcohol, Smoking and Substance In-
volvement Screening Test (ASSIST [28]). The ASSIST is a valid screening test for psychoactive
substances in individuals who use a number of different substances and a valid measure of se-
verity of dependence for the substance that is most problematic for the person concerned. The
validity of this scale has been proven across different cultures, including the Australian context
[29]. A cut-off score of 2 has been demonstrated to have the best sensitivity and specificity
for DSM-IV cannabis use disorder among people with FEP [30]. Using baseline data of this
study, a cutoff score in the ASSIST set at 2 had a sensitivity of 83% and a specificity of 87%
for the diagnosis of cannabis disorder [31]. Sensitivity and specificity values above 0.8 are con-
sidered optimal for screening tools [32].
Statistical analyses
To compare patients with and without cannabis misuse at each assessment, we used Student's
t-test and the chi-square test, as appropriate. In the instance of notably skewed distributions,
logarithmic or square root transformations were performed. Analyses were performed using
SPSS − version 18.0 (SPSS Inc).
To compare change trajectories of social functioning over time for each cannabis group, we
used multilevel linear growth curve modeling [33], estimated using HLM 7.01 (SSI Inc.). Thus,
measurement occasion (i.e., time) was a within-person predictor and baseline cannabis disor-
der diagnosis was a between-person predictor. The Level-1 (within-person) model equation
was as follows:
SOFASti ¼ p0i þ p1i  ðTimetiÞ þ eti
Here, a person i’s SOFAS score at assessment t is modeled as a function of an intercept (π0i)
and a slope (π1i) representing the linear effect of time (Timeti: 0 = baseline, 5 = 30 months, with
equal intervals for each intermediate follow-up). Thus, the Level-1 intercept (π0i) reflects per-
son i’s baseline level of social functioning (i.e., SOFAS at Timeti = 0), whereas the Level-1 slope
(π1i) reflects person i's rate of change in SOFAS over 30 months. The intercept and slope were
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allowed to vary randomly across persons and modeled as a function of cannabis disorder
group at Level-2, as follows:
p0i ¼ b00 þ b01ðCannabis MisuseiÞ þ r0i
p1i ¼ b10 þ b11ðCannabis MisuseiÞ þ r1i
Here, the Level-1 intercept and slope were modeled as function of a dummy variable, Cannabis
Misusei (1 = cannabis misuse; 0 = no cannabis misuse), indicating whether person i was diag-
nosed with a DSM-IV cannabis use disorder at baseline. Thus, β00 is an estimate of SOFAS at
baseline among FEP patients without cannabis disorder, whereas β01 represents how much pa-
tients with cannabis disorder differ from those without cannabis disorder in terms of baseline
SOFAS. Similarly, β10 is an estimate of the rate of change in SOFAS over the 30-month follow-
up among individuals without cannabis misuse disorder, whereas β11 reflects the difference in
SOFAS change trajectory among patients with a cannabis misuse disorder.
Results
Descriptive statistics and group differences in baseline characteristics
Forty-two (51.9%) patients had a baseline DSM-IV diagnosis of cannabis use disorder (abuse or
dependence). Demographic and other baseline characteristics for the entire sample and sepa-
rately by cannabis disorder group are presented in Table 1. As shown in Table 1, the cannabis
groups differed on a number of baseline measures. Specifically, relative to patients without can-
nabis misuse, a (marginally) significantly higher proportion of patients with cannabis disorder
were: a) assigned to the RPT condition (p = .096); b) diagnosed with schizophrenia (p = .005),
bipolar disorder (p = .048), or substance-induced psychotic disorder (p = .089); and c)
diagnosed with amphetamine misuse (p = .003), hallucinogen misuse (p = .003), or cocaine mis-
use (p = .089). In contrast, cannabis disorder patients were less likely to be diagnosed with psy-
chotic disorder not otherwise specified (p = .030), or a major depressive episode with psychotic
features (p = .059). Finally, patients in the cannabis misuse group were taking significantly
higher doses, calculated using chlorpromazine (CPZ) equivalents, of antipsychotic medication
(p<. 020) and were significantly older than patients without a baseline cannabis disorder diag-
nosis (p = .032). There were no other group differences on demographics, diagnoses, or mea-
sures of baseline functioning.
Group differences in social functioning (SOFAS) at each assessment
Fig 1 displays mean SOFAS scores (and 95% Confidence Intervals) for FEP patients with and
without comorbid cannabis disorder diagnosis at each assessment from baseline to 30-month
follow-up. Patients with and without cannabis disorder did not differ significantly in their so-
cial functioning at baseline (p = .763; see Table 1), or at the 6-month, 12-month, or 18-month
follow-ups (ps>. 12). However, after 24 months, patients with a baseline diagnosis of canna-
bis disorder had significantly lower social functioning than those without cannabis disorder,
Mdiff = −12.17; SEdiff = 4.80, t(56) = −2.54, p = .014, and this difference remained significant at
30-month follow-up,Mdiff = −11.09; SEdiff = 5.21, t(51) = −2.13, p = .038 (see Fig 1). These re-
sults suggest that FEP patients with and without cannabis disorder showed different trajecto-
ries of social functioning over 30 months.
Cannabis Misuse and Social Functioning in FEP
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Group differences in social functioning (SOFAS) change trajectories
over the 30-month follow-up
To directly compare the trajectories of social functioning over the 30-month follow-up for pa-
tients with and without a comorbid cannabis misuse, we used a multilevel linear growth curve
Table 1. Demographic and baseline clinical characteristics of the total sample and by cannabis misuse group.
Total Sample
(N = 81)
Cannabis misuse
(n = 42)
No Cannabis
misuse (n = 39)
Dichotomous variables n % n % n % Test of group difference
Treatment group (RPT) 41 50.6 25 59.5 16 41.0 χ2(1, N = 81) = 2.77, p = .096
Gender (male) 51 63.0 30 71.4 21 53.8 χ2(1, N = 81) = 2.68, p = .102
Employment status (unemployed) 35 43.2 20 47.6 15 38.4 χ2(1, N = 81) = 0.69, p = .406
Psychotic disorder diagnosis
Schizophrenia 27 33.3 20 47.6 7 17.9 χ2(1, N = 81) = 8.01, p = .005
Schizophreniform disorder 9 11.1 3 7.1 6 15.4 χ2(1, N = 81) = 1.39, p = .238
Schizoaffective disorder 4 4.9 1 2.4 3 7.7 χ2(1, N = 81) = 1.22, p = .270
Major depression with psychotic features 9 11.1 2 4.8 7 17.9 χ2(1, N = 81) = 3.56, p = .059
Bipolar disorder 4 4.9 4 9.5 0 0.0 χ2(1, N = 81) = 3.91, p = .048
Delusional disorder 1 1.2 1 2.4 0 0.0 χ2(1, N = 81) = 0.94, p = .332
Substance-induced psychotic disorder 3 3.7 3 7.1 0 0.0 χ2(1, N = 81) = 2.89, p = .089
Psychotic disorder not otherwise specified 24 29.6 8 19.0 16 41.0 χ2(1, N = 81) = 4.69, p = .030
Other substance use diagnosis
Alcohol 20 24.7 12 28.6 8 20.5 χ2(1, N = 81) = 0.71, p = .401
Cocaine 3 3.7 3 7.1 0 0.0 χ2(1, N = 81) = 2.89, p = .089
Opioid 6 7.4 4 9.5 2 5.1 χ2(1, N = 81) = 0.57, p = .450
Amphetamine 15 18.5 13 31.0 2 5.1 χ2(1, N = 81) = 8.94, p = .003
Hallucinogen 12 14.8 11 26.2 1 2.6 χ2(1, N = 81) = 8.95, p = .003
Inhalant 2 2.5 2 4.8 0 0.0 χ2(1, N = 81) = 1.90, p = .168
Sedative, hypnotic or anxiolytic 1 1.2 1 2.4 0 0.0 χ2(1, N = 81) = 0.94, p = .332
Polysubstance 2 2.5 1 2.4 1 2.6 χ2(1, N = 81) = 0.00, p = .985
Other 1 1.2 1 2.4 0 0.0 χ2(1, N = 81) = 0.94, p = .332
Continuous variables M SD M SD M SD Test of group difference
Age 20.11 3.05 20.81 2.53 19.36 3.40 t(69.99) = 2.17, p = .0.34a
Years of education 12.06 1.77 12.14 1.62 11.97 1.94 t(79) = 0.43, p = .671
FSIQb,e 98.19 8.91 98.63 7.86 97.71 10.01 t(71) = 0.44, p = .663
PAS (average)b 0.29 0.16 0.30 0.16 0.28 0.17 t(62) = 0.59, p = .557
DUPb,d 384.81 567.95 418.49 630.71 349.09 500.16 t(66) = 0.01, p = .991c
BPRS 34.81 7.48 35.67 7.62 33.90 7.32 t(79) = 1.12, p = .265c
SANS 4.60 3.49 4.40 3.61 4.82 3.39 t(79) = -0.53, p = .596
MADRS 10.43 9.13 11.43 10.14 9.36 7.88 t(79) = 1.02, p = .311
SOFAS 63.17 15.89 63.69 17.50 62.62 14.17 t(79) = 0.30, p = .763
Antipsychotic dosage (CPZ equivalents) 382.35 285.53 446.26 348.56 299.27 139.06 t(52.41) = 2.397, p = .020a
Note: DUP, Duration of Untreated Psychosis; FSIQ, Full Scale IQ (see the text for tests abbreviations).
a t-test reported with correction for unequal group variances
b Due to missing data, DUP n = 68 (35 & 33 per group); premorbid IQ n = 73 (38 & 35 per group); PAS n = 64 (36 & 28 per group);
c t-test based on logarithmic-transformed data due to the skewness of the raw data.
d Estimated on the basis of time between onset of symptoms and entry into the service.
e Estimated by the Wechsler Test of Adult Reading.
doi:10.1371/journal.pone.0122404.t001
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model (see above). Results of this analysis are displayed in Table 2, and revealed no effect of
cannabis misuse on the intercept (p = .387), indicating that cannabis misuse was not associat-
ed with social functioning (SOFAS) at baseline (see also t-test in Table 1). However, cannabis
disorder was significantly negatively related to the slope of time (p = .002), indicating that pa-
tients with cannabis misuse showed lesser change in social functioning over time (see Table 2,
Model 1). A further simple slopes analysis revealed that whereas a significant improvement in
social functioning over time was observed among patients without cannabis misuse, B = 2.68,
t(79) = 5.14, p<. 001, 95% CI [1.65, 3.72], patients diagnosed with cannabis misuse showed
no significant change in their level of social functioning over the 30-month follow-up,
B = –0.12, t(79) = –0.18, p = .858, 95% CI [–1. 50, 1.25]. Fig 2 displays the simple slopes (with
95% CIs) reflecting change in social functioning over time for each group.
According to the ASSIST scale, 14 (17.3%) subjects changed their pattern of cannabis mis-
use over the 30 months follow up. Eleven of those 14 subjects changed from cannabis misuse to
no cannabis misuse (i.e., their ASSIST− cannabis score was 2 at baseline but decreased
to< 2 at 30-month follow-up). The remaining three subjects, who did not meet criteria for
cannabis misuse (based on DSM criteria) at baseline, were classified as problematic users
(based on ASSIST − cannabis scale) at 30 months follow-up. The small sample size for these
subgroups precludes a separate statistical analysis. However, the main analyses were rerun
without these 14 subjects and similar results were obtained to those reported above: patients
without cannabis disorder showed significant improvement over time in SOFAS, B = 2.84, t
(37) = 4.52, p<. 001, 95% CI [1.57, 4.12], whereas patients diagnosed with comorbid cannabis
Fig 1. Mean social functioning (SOFAS) scores by cannabis group at each time-point. Error bars represent 95%Confidence Intervals. Differences
between cannabis disorder groups at 24 and 30 months are statistically significant at p<.05.
doi:10.1371/journal.pone.0122404.g001
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Table 2. Results of Separate Multilevel Linear Growth Curve Models Predicting Change in Social Functioning over 30-Months from Cannabis Mis-
use and other Baseline Measures Individually.
95% CI
Predictor / Parameter Estimate (SE) LL UL p
Model 1 Cannabis misuse
Effect on intercept (β01) 2.68 (3.08) –3.45 8.81 .387
Effect on slope (β11) –2.81 (0.87) –4.54 –1.08 .002
Model 2 Treatment group
Effect on intercept (β01) –2.64 (3.12) –8.85 3.57 .400
Effect on slope (β11) 0.06 (0.96) –1.85 1.98 .946
Model 3 Schizophrenia
Effect on intercept (β01) –10.12 (2.95) –16.00 –4.25 <. 001
Effect on slope (β11) –1.03 (1.02) –3.07 1.00 .315
Model 4 MDEP
Effect on intercept (β01) 0.64 (4.30) –7.92 9.20 .882
Effect on slope (β11) 0.92 (1.13) –1.33 3.17 .417
Model 5 Bipolar disorder
Effect on intercept (β01) 11.72 (3.29) 5.17 18.27 <. 001
Effect on slope (β11) –1.80 (0.74) –3.28 –0.33 .017
Model 6 SIPD
Effect on intercept (β01) 2.34 (12.09) –21.73 26.41 .847
Effect on slope (β11) –0.91 (0.98) –2.86 1.03 .353
Model 7 PDNOS
Effect on intercept (β01) 0.02 (3.42) –6.79 6.84 .995
Effect on slope (β11) 0.73 (1.12) –1.50 2.96 .516
Model 8 Cocaine misuse
Effect on intercept (β01) 10.52 (5.52) –0.47 21.51 .060
Effect on slope (β11) –3.82 (1.93) –7.67 0.02 .051
Model 9 Amphetamine misuse
Effect on intercept (β01) 1.78 (4.94) –8.05 11.62 .719
Effect on slope (β11) –0.16 (1.20) –2.54 2.22 .895
Model 10 Hallucinogen misuse
Effect on intercept (β01) –2.59 (4.54) –11.63 6.46 .571
Effect on slope (β11) –1.86 (1.59) –5.02 1.30 .246
Model 11 Age
Effect on intercept (β01) –0.62 (0.46) –1.54 0.30 .184
Effect on slope (β11) –0.10 (0.14) –0.38 0.18 .479
Model 11 Antipsychotic dosage
Effect on intercept (β01) –8.32 (6.01) –20.31 3.67 .171
Effect on slope (β11) –1.84 (1.73) –5.30 1.62 .293
Note.
MDEP = major depressive episode with psychotic features.
SIPD = substance-induced psychotic disorder.
PDNOS = psychotic disorder not otherwise specified.
Approx. df = 79 for all models except antipsychotic dosage, where df = 67 due to missing data
doi:10.1371/journal.pone.0122404.t002
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disorder at baseline showed no significant change in social functioning over the course of the
30-month follow-up, B = –0.96, t(37) = –1.02, p = .315, 95% CI [–2.88, 0.95].
Controlling for possible confounding variables
Cannabis misuse was associated with other baseline variables (see Table 1), which may them-
selves have been related to changes in social functioning over time and could therefore account
for the effect of cannabis misuse. To explore this, we ran additional multilevel growth curve
analyses with each baseline variable that was associated with cannabis misuse at p<. 10 (see
Table 1). These models were identical to the first multilevel growth curve model (see model
equations, above). However, at Level-2 cannabis misuse was replaced with one of the following
baseline measures: treatment group. schizophrenia diagnosis, bipolar disorder diagnosis, sub-
stance-induced psychotic disorder diagnosis, psychotic disorder not otherwise specified diag-
nosis, cocaine misuse diagnosis, amphetamine misuse diagnosis, hallucinogen misuse
diagnosis, age, or antipsychotic medication dosage. Separate models were conducted with each
variable entered individually as a predictor at Level-2.
Results of these separate models are displayed in Table 2. Results of Model 3 revealed a sig-
nificant negative effect of schizophrenia diagnosis on the intercept (p<. 001), meaning that pa-
tients diagnosed with schizophrenia had lower social functioning at baseline compared with
other patients. However, schizophrenia diagnosis was not significantly related to the SOFAS
change slope (p = .315). Results of Model 5 showed that bipolar disorder diagnosis was
Fig 2. Model predicted change trajectories of social functioning (SOFAS) from baseline to 30 months by cannabis group.Dashed lines represent
95% Confidence Intervals.
doi:10.1371/journal.pone.0122404.g002
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positively related to the intercept (p<. 001), indicating that patients with bipolar disorder had
significantly better baseline social functioning compared with other patients. However, bipolar
disorder diagnosis was also related negatively to the change slope (p = .017), such that patients
with bipolar disorder showed less improvement in their social functioning over time than
other patients. Finally, results of Model 8 revealed marginally significant effects of cocaine mis-
use diagnosis on the intercept (p = .060) and slope (p = .051), which were positive and negative,
respectively. Thus, similar to the findings for bipolar disorder, patients diagnosed with cocaine
misuse began with somewhat higher levels of social functioning and showed somewhat less
change in their social functioning over time.
To assess whether the effect of cannabis misuse on change in social functioning was inde-
pendent of these possible confounding variables, we ran a final multilevel growth curve model
with cannabis misuse plus all other predictors shown in Table 2. Results of this combined
model are shown in Table 3. Cannabis misuse was still significantly negatively related to the
Table 3. Results of Combined Multilevel Linear Growth Curve Model Predicting Change in Social Functioning over 30-Months from Cannabis Mis-
use and other Baseline Measures Simultaneously.
95% CI
Predictor / Parameter Estimate (SE) LL UL p
Effect on Intercept
Cannabis misuse (β01) 8.78 (3.93) 0.90 16.66 .030
Treatment group (β02) –5.18 (3.38) –11.96 1.59 .131
Schizophrenia (β03) –16.76 (4.60) –25.98 –7.53 <.001
MDEP (β04) –9.10 (6.31) –21.74 3.54 .155
Bipolar disorder (β05) –4.79 (7.70) –20.22 10.63 .536
SIPD (β06) –23.15 (10.02) –43.22 –3.08 .025
PDNOS (β07) –10.66 (4.66) –20.01 –1.32 .026
Cocaine (β08) 15.98 (8.37) –0.79 32.76 .061
Amphetamine (β09) 1.27 (5.09) –8.92 11.46 .804
Hallucinogen (β010) –5.88 (5.59) –17.07 5.31 .297
Age (β011) –0.73 (0.59) –1.91 0.46 .224
Antipsychotic medication (β012) –8.10 (6.31) –20.75 4.54 .205
Effect on Slope
Cannabis misuse (β11) –3.21 (1.37) –5.95 –0.47 .023
Treatment group (β12) 0.96 (1.18) –1.40 3.33 .419
Schizophrenia (β13) 0.02 (1.56) –3.11 3.16 .988
MDEP (β14) 0.83 (2.09) –3.36 5.02 .693
Bipolar disorder (β15) –0.62 (2.46) –5.54 4.30 .801
SIPD (β16) –0.02 (3.28) –6.59 6.54 .994
PDNOS (β17) 0.28 (1.58) –2.88 3.44 .858
Cocaine (β18) –3.08 (2.66) –8.41 2.25 .252
Amphetamine (β19) 2.01 (1.64) –1.28 5.30 .227
Hallucinogen (β110) –1.15 (1.86) –4.88 2.58 .538
Age (β111) 0.11 (0.20) –0.29 0.51 .592
Antipsychotic medication (β112) 0.29 (2.03) –3.79 4.36 .888
Note. MDEP = major depressive episode with psychotic features.
SIPD = substance-induced psychotic disorder.
PDNOS = psychotic disorder not otherwise specified.
Approx. df = 56.
doi:10.1371/journal.pone.0122404.t003
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SOFAS change slope (p = .023) even after controlling for all other baseline measures that were
(marginally) significantly associated with cannabis misuse. Thus, independent of other baseline
characteristics associated with cannabis misuse, patients diagnosed with cannabis disorder
showed significantly lower improvement in social functioning over time. No other baseline var-
iables were significantly associated with the SOFAS change slope.
Discussion
The profile of our sample, FEP patients with an average age of 20 years, is one of high risk for
cannabis misuse. In fact, half of our sample had a cannabis use disorder diagnosed at baseline.
Although cannabis misuse was not associated with social functioning at baseline assessment, it
was an independent predictor of long-term social functioning. Over a 30-month follow-up,
FEP patients without cannabis misuse showed significant improvements in their social func-
tioning, whereas patients who had been diagnosed with cannabis disorder at baseline displayed
no such improvement. Cannabis misuse was still significantly associated with social function-
ing change over the 30-month follow-up even after controlling for all other baseline potential
confounders, including pharmacological and psychological treatments.. While patients with
and without cannabis disorder showed divergent social functioning trajectories from the first
follow-up, the patient groups only differed significantly in their levels of social functioning
after 24 months.
In agreement with our results, most recent FEP studies have found a detrimental effect of
cannabis misuse on functioning [6–8]. However, our findings are at odds with other studies
[10,11]. A possible explanation for this discrepancy is that these studies, assessed patients’ so-
cial functioning using a quality of life scale or a scale that integrates symptoms and social func-
tioning. Interestingly, another study from the same group [8] found that the relationship
between cannabis and social functioning, when assessed with a quality of life scale, was mediat-
ed by symptoms, whereas when assessed in terms of productivity (i.e. being employed or in
school) cannabis use at initial assessment emerged as an independent predictor of functional
outcome at 1-year and 2-year follow-ups. Similarly, the impact of baseline cannabis misuse on
long-term social functioning might be concealed when an overall scale of functioning (which
includes symptoms) is used (for example [11].
While the deleterious effects of cannabis on psychosocial functioning and psychopathology
have been described in young people from the general population [34], the negative impact on
social functioning might be particularly important in young people with recent onset of psy-
chosis, who are known to be prone to psychosocial deterioration. According to the ‘critical pe-
riod’ hypothesis [35], symptomatic and psychosocial deterioration progresses rapidly during
the early phase of psychosis. In the present study, young people with no problematic cannabis
use significantly improved their social outcomes over time, whereas those with cannabis misuse
did not improve their overall social outcomes. In this sense it may be said that cannabis misuse
precludes patients from the benefits expected from specialized FEP services. Consequently, this
stresses the need to include specific interventions for the management of cannabis misuse in
early intervention services. However, current psychosocial interventions may have limited effi-
cacy in this population [36] and the few available studies of specialized substance abuse treat-
ments for FEP patients have not demonstrated substantially better rates of reduction or
abstinence in substance use compared with non-specialized treatments [37,38]. At the same
time, it is worth noting that some behavioural treatments for drug abuse in people with severe
mental disorders have proven to be efficacious both in reducing substance use and improving
community-functioning [39]. Interestingly, Gonzalez-Pinto et al. [12] found that stopping can-
nabis use after the first psychotic episode contributed to improvement in long-term functional
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outcomes. In the present study, the subjects who according to the ASSIST scale stopped their
problematic cannabis use over the 30-month follow up were only 11 (13.6%) out of 81. The
small sample size of this subgroup precludes any reliable analysis.
The means by which cannabis misuse affects social functioning remains to be elucidated. A
potential mechanism by which cannabis misuse prevents social improvements might be by im-
pairing some cognitive processes, which have been associated with functional outcomes in FEP
[40]. However, recent meta-analyses have demonstrated that patients with schizophrenia and a
comorbid cannabis use disorder have the same or lower levels of cognitive impairment as their
non-using counterparts [41,42]. Alternatively, cannabis may affect social outcomes by exacer-
bating of symptoms or other clinical features. Nevertheless, cannabis has only been inconsis-
tently associated with symptoms and other clinical outcomes, other than relapse and treatment
non-adherence [5]. In the present study symptom severity or treatment adherence were not as-
sociated with social functioning. Therefore, it is likely that other variables not analysed in this
study may help to understand the mechanisms underlying the association between cannabis
misuse and social functioning. Speculatively, one possible mechanism is intrinsic motivation.
While the evidence for an amotivational syndrome due to cannabis use in the general popula-
tion is conflicting [43], the effects in those patients characteristically affected by motivational
deficits (e.g., FEP patients) maybe more pronounced. In support of this idea, intrinsic motiva-
tion has been suggested as a decisive mechanism for explaining the relationship between neu-
rocognition and psychosocial functioning in schizophrenia [44].
There are some limitations to this study. First, this study uses a secondary analysis of data
from EPISODE-II, a RCT designed to evaluate the effectiveness of an individual and family-
based relapse prevention therapy for relapse prevention in clinically remitted FEP patients. Sec-
ond, the sample size was modest and the influence of variables with small effect sizes might re-
main undetected. We have reported confidence intervals to show the uncertainty of the results
following the recommendations of some statisticians [45]. Third, cannabis misuse was deter-
mined by a DSM diagnosis, which arguably can only detect the most severe cases of cannabis
misuse. Nevertheless, the percentage of cases detected is not below other first-episodes studies
[3]; on the other hand, there was a high degree of consistency between the DSM-IV cannabis
misuse disorder diagnosis and the ASSIST-cannabis scale, a valid screening tool for the identifi-
cation of problematic substance use. Fourth, other variables not examined in the present study,
such as specific cognitive dimensions, tobacco use, family support or psychological variables,
may also have an impact in social functioning and should be considered in future studies. Fi-
nally, the current findings may be restricted to FEP patients after the remission of acute psy-
chotic symptoms receiving care in a specialized first episode service.
On the whole, this study shows that cannabis misuse was highly prevalent (> 50%) within a
sample of FEP patients after the remission of acute psychotic symptoms. While an overall im-
provement in social functioning was observed in this sample, in the context of an early interven-
tion service, those patients with baseline cannabis misuse did not improve their long-term
social outcomes during the study period. Therefore, there is a need to develop effective inter-
ventions to reduce cannabis misuse and, ultimately, to improve social outcomes, which is an es-
sential goal for specialized services that provide care for young people with psychosis.
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